Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial
- 1 August 1996
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 348 (9027) , 563-566
- https://doi.org/10.1016/s0140-6736(96)02005-3
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosisBritish Journal of Cancer, 1996
- Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.Journal of Clinical Oncology, 1995
- Treatment-related deaths in small cell lung cancer trials: can patients at risk be identified?Lung Cancer, 1994
- Bioavailability of low-dose oral etoposide.Journal of Clinical Oncology, 1993
- An overview of prognostic factors in small cell lung cancerBritish Journal of Cancer, 1990
- A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.Journal of Clinical Oncology, 1989
- Variable bioavailability following repeated oral doses of etoposideEuropean Journal of Cancer and Clinical Oncology, 1985
- Current status of therapy for small cell carcinoma of the lungCancer, 1984
- Radiotherapy alone or with chemotherapy in the treatment of small-cell carcinoma of the lung.British Journal of Cancer, 1979